Search for a trial

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Metastatic Breast Cancer

This study has been transitioned to CTIS with ID 2023-506752-24-00 check the CTIS register for the current data. 1) Objective: To compare pembrolizumab plus chemotherapy to placebo plus chemotherapy with respect to PFS